found Documents: 389

Announcements & Press Releases, Group, Press Releases | 16 Jan 2017

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors

1 item

Change of Directors London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Execut

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Jan 2017

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

1 item

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Jan 2017

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

1 item

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China. Sulfatinib

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 16 Jan 2017

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

1 item

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol®) in second-line patients

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Jan 2017

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

1 item

London: Tuesday, January 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematolo

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Dec 2016

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

1 item

Press Release London: Tuesday, December 6, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spl

View Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Nov 2016

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)

1 item

Press Release London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer (“NSCLC”) clinical studies will be presented at WCLC in Vienn

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Nov 2016

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting

1 item

Press Release London: Monday, November 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokineti

View Announcement (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 31 Oct 2016

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

1 item

Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen

View Announcement (PDF)

Announcements & Press Releases, Group | 2 Aug 2016

Change of Non-executive Directors

1 item

London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha

View Announcement (PDF)

Announcements & Press Releases, Group | 2 Aug 2016

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

1 item

Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment. Innovation Platform – Seven drug candidates in 25

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Aug 2016

Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program

1 item

First global pivotal Phase III in c-Met-driven papillary renal cell carcinoma (“PRCC”) to be initiated in the near future London: Monday, August 1, 2016: Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 glo

View Announcement (PDF)

Announcements & Press Releases, Group | 5 Jul 2016

Chi-Med to Announce 2016 Half-Year Financial Results

1 item

London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Jun 2016

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

2 items

Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encouraging data from initial small Phase II studies of savolitinib in combination with Tagrisso or Iressa in c-Met-am

Savolitinib Clinical Trials Summary (PDF)View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 May 2016

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

1 item

London: Friday, May 13, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced

View Announcement (PDF)

Group, Press Releases | 4 May 2016

Chi-Med to Participate in Two Healthcare Investor Conferences in May

London—May 2, 2016—Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May. Conference Details: E

Announcements & Press Releases, Group | 13 Apr 2016

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

1 item

London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 12 Apr 2016

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

1 item

London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli

View Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 22 Mar 2016

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

2 items

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT

View Announcement (PDF)View Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 21 Mar 2016

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

1 item

London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s

View Announcement (PDF)

Announcements & Press Releases, Group | 18 Mar 2016

Final Prospectus

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 17 Mar 2016

Pricing of U.S. Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group, Press Coverage | 17 Mar 2016

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

1 item

Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app

View Announcement (PDF)

Announcements & Press Releases, Group | 15 Mar 2016

2015 Annual Report and Notice of Annual General Meeting

1 item

London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The

View Announcement (PDF)

Announcements & Press Releases, Group | 7 Mar 2016

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 4 Mar 2016

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

1 item

Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f

View Announcement (PDF)

Announcements & Press Releases, Group | 4 Mar 2016

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 2 Mar 2016

Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer

1 item

London: Wednesday, 2 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated an open-label Phase II clinical trial to evaluate t

View Announcement (PDF)

Announcements & Press Releases, Group | 1 Mar 2016

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

View Full Announcement (PDF)

Announcements & Press Releases, Group | 1 Mar 2016

Final Results for the year ended 31 December 2015

5 items

Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III

View Full Announcement (PDF)View Announcement Summary (PDF)View Chairman's Statement (PDF)View Operations Review (PDF)View Financial Statements (PDF)

Announcements & Press Releases, Group | 11 Feb 2016

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 15 Jan 2016

Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia

1 item

London: Friday, 15 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated a Phase I trial in Australia in patients with haema

View PDF

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Dec 2015

Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients

1 item

London: Friday, 18 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) regist

View Announcement (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 9 Dec 2015

US$105 million Shanghai land compensation agreement

1 item

Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Dec 2015

Initiation of fruquintinib Phase III registration trial in non-small cell lung cancer

1 item

London: Tuesday, 8 December 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated FALUCA, a Phase III registration study for fruqu

View Announcement (PDF)

Announcements & Press Releases, Group | 13 Nov 2015

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

1 item

The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

View Full Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Nov 2015

Chi-Med initiates sulfatinib U.S. clinical trials

1 item

London: Friday, 6 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 30 Oct 2015

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

1 item

Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 30 Oct 2015

Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers

1 item

London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has successfully completed its first-in-human Phase I clini

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 Oct 2015

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

1 item

London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt

View Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 16 Oct 2015

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

1 item

Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti

View Announcement (PDF)

Announcements & Press Releases, Group | 16 Oct 2015

Shareholders' Circular and Notice of Extraordinary General Meeting

1 item

London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U

View Announcement (PDF)

Announcements & Press Releases, Group | 16 Oct 2015

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Oct 2015

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma

1 item

Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha

View PDF

Announcements & Press Releases, Group | 8 Oct 2015

Winner of International Company of the Year 2015, AIM

At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners

Announcements & Press Releases, Oncology / Immunology | 14 Sep 2015

Fruquintinib Phase II clinical results in colorectal cancer to be presented at the 2015 European Cancer Congress

1 item

London: Monday, 14 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present the detailed clinical results of its Phase II proo

View PDF

Announcements & Press Releases, Oncology / Immunology | 2 Sep 2015

Second proof-of-concept trial of fruquintinib achieves its primary endpoint

1 item

London: Wednesday, 2 September 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proo

View PDF

Announcements & Press Releases, Oncology / Immunology | 19 Aug 2015

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project

1 item

London: Wednesday, 19 August 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that, Hutchison MediPharma Limited (“HMP”), its R&D subsidiary, has received notice from Janssen Pharmaceutical, Inc. (Janssen) of

View PDF

Announcements & Press Releases, Group | 28 Jul 2015

Interim Results for the Six Months Ended 30 June 2015

1 item

For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 Jul 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med

1 item

London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui

PDF

1 2 3 4 5

7 8